Abstract
Background The novel Disseminated Intravascular Coagulation (DIC) score [platelet count, prolonged prothrombin time, D-dimer, and fibrinogen] and Sepsis Induced Coagulopathy (SIC) score [platelet count, International normalized ratio, and Sequential organ failure assessment score] are markers of coagulopathy, which, for the first time, are explored in line with the COVID-19 disease outcomes. The correlation of D-dimer with these findings is also studied.
Patients and methods A retrospective analysis of hospital-based records of 168 COVID-19 patients. Data including D-dimer, routine investigations, DIC and SIC scorings (all within three days of admission) were collected and correlated with the outcomes. The study was conducted in a tertiary care center catering to population of North India.
Results Higher DIC score (1·59 ± 1·18 v/s 0·96 ± 1·18), SIC score (1·60 ± 0·89 v/s 0·63 ± 0·99), and D-dimer titers (1321·33 ± 1627·89 v/s 583·66 ± 777·71 ng/ml) were significantly associated with severe COVID-19 disease (P<0·05). DIC score and SIC score ≥ 1, and D-dimer ≥ 1315 ng/ml for severe disease; DIC score ≥ 1, SIC score ≥ 2, and D-dimer ≥ 600 ng/ml for Pulmonary Embolism (PE); and DIC score and SIC score ≥ 1, and D-dimer level ≥ 990 ng/ml for mortality were the respective cut-off values we found from our study.
Conclusion Higher DIC scores, SIC scores, and D-dimer values are associated with severe COVID-19 disease, in-hospital mortality, and PE risk. They can serve as easily accessible early markers of severe disease and prioritize hospital admissions in the presently overburdened scenario, and may be used to develop prognostic prediction models.
Highlights DIC scores, SIC scores, and D-dimer values are hereby studied in association with COVID-19 disease severity, in-hospital mortality, and PE risk. They serve as easily accessible early markers of severe disease and prioritize hospital admissions in the presently overburdened scenario, and may be used to develop prognostic prediction models.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Ethical Committee of All India Institute of Medical Sciences Rishikesh approved the study prior to data collection.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Mob: +91-9997139399
Mob: +91-9868999488
Mob: +91-8890293424
Mob: +91-9655007473
Data Availability
We have access to the data used in the manuscript.
